Urgent

Idiopathic inflammatory myopathy

Myositis · Neurology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A group of autoimmune muscle diseases including dermatomyositis, polymyositis, immune-mediated necrotising myopathy and inclusion body myositis, presenting with proximal weakness and raised creatine kinase. Associated with malignancy, interstitial lung disease and specific myositis antibodies that guide prognosis.

Red flags

  • Respiratory muscle weakness or rapidly progressive ILD (especially anti-MDA5)
  • Dysphagia with aspiration risk
  • Associated malignancy (TIF1-gamma antibody)
  • Rhabdomyolysis with renal impairment
  • Cardiac involvement

Assessment

Differential diagnosis

  • Inclusion body myositis (distal/asymmetric, treatment-resistant)
  • Muscular dystrophy
  • Statin-associated or toxic myopathy
  • Endocrine myopathy (thyroid, Cushing's)
  • Motor neuron disease
  • Metabolic myopathy

Investigations

  • Creatine kinase (markedly elevated except in IBM)
  • EMG (myopathic units with irritability)
  • Myositis-specific and associated antibodies (Jo-1, Mi-2, MDA5, HMGCR, SRP, TIF1-gamma)
  • MRI muscle to guide biopsy
  • Muscle biopsy for definitive diagnosis
  • Malignancy screen (especially dermatomyositis) and HRCT chest for ILD

Management

  • Recognise subacute symmetrical proximal weakness with raised creatine kinase
  • Look for dermatomyositis skin signs (Gottron's papules, heliotrope rash)
  • Confirm with EMG, MRI-guided muscle biopsy and myositis antibodies
  • Screen for associated malignancy and interstitial lung disease
  • Assess swallowing and respiratory muscle function
  • Start high-dose corticosteroids as first-line therapy
  • Add a steroid-sparing immunosuppressant early
  • Use IVIG for severe, refractory or dysphagic dermatomyositis
  • Treat anti-MDA5 disease aggressively given rapidly progressive ILD risk
  • Provide physiotherapy and monitor for inclusion body myositis if steroid-unresponsive

Drugs & doses

Prednisolone 1 mg/kg PO daily (up to 60-80 mg), tapering over months
Methylprednisolone 1 g IV daily for 3 days in severe disease
Methotrexate 15-25 mg weekly or azathioprine 2-3 mg/kg/day (steroid-sparing)
IVIG 2 g/kg over 2-5 days for refractory/dysphagic disease
Mycophenolate or rituximab for refractory or ILD-associated disease

Disposition

Specialist neuromuscular/rheumatology clinic. Admission for respiratory or swallowing compromise. Malignancy and ILD surveillance.

Complications & pitfalls

  • Respiratory failure and interstitial lung disease
  • Aspiration pneumonia from dysphagia
  • Associated malignancy
  • Steroid myopathy and immunosuppression complications
  • Permanent muscle atrophy

Exam pearls

  • Inclusion body myositis is distal, asymmetric and steroid-resistant; suspect it when treatment fails
  • Dermatomyositis carries a significant malignancy risk; screen thoroughly
  • Anti-MDA5 dermatomyositis can cause rapidly fatal lung disease and needs aggressive treatment
  • A normal or only mildly raised creatine kinase does not exclude IBM

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.